

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10565900
Filing Date	2006-01-24
First Named Inventor	Bridon et al.
Art Unit	1654
Examiner Name	Christina Bradley
Attorney Docket Number	C2077-7016US

U.S.PATENTS						Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.						Add		
U.S.PATENT APPLICATION PUBLICATIONS						Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.						Add		
FOREIGN PATENT DOCUMENTS						Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	1570532	GB		1980-07-02	Dainippon Pharmaceutical Co. LTD.		<input type="checkbox"/>
If you wish to add additional Foreign Patent Document citation information please click the Add button						Add		
NON-PATENT LITERATURE DOCUMENTS						Remove		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T ⁵	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number		10565900
	Filing Date		2006-01-24
	First Named Inventor		Bridon et al.
	Art Unit		1654
	Examiner Name		Christina Bradley
	Attorney Docket Number		C2077-7016US

	1	Notice of Opposition for European Patent Application No. 04801809.7 dated 04-29-2010.	<input type="checkbox"/>
	2	CHUANG, et al. (May 2002) "Pharmaceutical Strategies Utilizing Recombinant Human Serum Albumin", Pharmaceutical Research, vol. 19(5), 569-577.	<input type="checkbox"/>
	3	KITIGAWA et al., (1976) "Enzyme Coupled Immunoassay of Insulin Using a Novel Coupling Reagent" J. Biochem., vol. 79, p. 233-236.	<input type="checkbox"/>
	4	SCHROER et al., (August 1979) "H-2-Linked Ir Gene Control of Antibody Responses to Insulin", The Journal of Immunology, vol. 123(2) p. 670-675.	<input type="checkbox"/>
	5	SHECHTER et al., (May 1978) "Fluorescent labeling of hormone receptors in viable cells: Preparation and properties of highly fluorescent derivatives of epidermal growth factor and insulin", Proc. Natl. Acad. Sci. vol 75(5). 2135-2139.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.